Journal of Clinical Endocrinology & Metabolism, Vol 78, 188-196, Copyright © 1994 by Endocrine Society

ARTICLES

Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study)

CA Meier, LE Braverman, SA Ebner, I Veronikis, GH Daniels, DS Ross, DJ Deraska, TF Davies, M Valentine and LJ DeGroot
National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, Maryland 20892.

Current diagnostic studies [radioiodine uptake and serum thyroglobulin (Tg) levels] for residual or metastatic thyroid tissue in patients with differentiated thyroid carcinoma require a hypothyroid status necessary for adequate endogenous TSH stimulation. However, almost all patients have symptoms of clinical hypothyroidism during this period. As shown in the present study, recombinant human TSH (rhTSH) allows stimulation of 131I uptake and Tg release from residual thyroid tissue in euthyroid patients. To assess safety, dosage, and preliminary efficacy, comparison was made of the stimulation of 131I uptake and Tg release after rhTSH administration and after T3 withdrawal in 19 patients after a recent thyroidectomy for differentiated thyroid carcinoma. Various doses (10-40 U) of rhTSH were injected im for 1-3 days in patients receiving suppressive doses of T3. Twenty-four hours after the last dose of rhTSH, 1-2 mCi 131I were administered, followed by a neck and whole body scan 48 h later. After discontinuing T3 for a median period of 19 days (range, 15-28), endogenous serum TSH levels were markedly elevated, and the patients were given a second dose of 131I and rescanned 48 h later. The injections of rhTSH were tolerated well. No major adverse effects were reported; nausea was reported in 3 (16%) and vomiting in 1 of the patients treated with high doses. The quality of life, as measured by two psychometric scales, was far better during rhTSH treatment than after T3 withdrawal. The peak levels of serum TSH (mean +/- SD) after a single dose of 10, 20, or 30 U were 127 +/- 19, 309 +/- 156, and 510 +/- 156 mU/L, respectively, and occurred 2-8 h after injection. Twenty-four hours after the injection, TSH levels decreased to 83 +/- 31, 173 +/- 73, and 463 +/- 148 mU/L in these treatment groups, respectively. The quality of the thyroid scans and the number of sites of abnormal 131I uptake were similar after rhTSH treatment and in the hypothyroid scans in 12 (63%) patients. Two additional sites of uptake in the chest and one in the thyroid bed, not visible on the hypothyroid scans, were identified in 3 (16%) patients after rhTSH. In 1 patient a focus of uptake was better visualized after rhTSH than after withdrawal. In 3 (16%) other patients, 1 lesion in the chest and 2 in the neck were seen only after T3 withdrawal.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				N. Emmanouilidis, J. A Muller, M. D Jager, S. Kaaden, F. A Helfritz, Z. Guner, H. Kespohl, W. Knitsch, W. H Knapp, J. Klempnauer, et al. Surgery and radioablation therapy combined: introducing a 1-week-condensed procedure bonding total thyroidectomy and radioablation therapy with recombinant human TSH Eur. J. Endocrinol., November 1, 2009; 161(5): 763 - 769. [Abstract] [Full Text] [PDF]

				C. C. Travis and M. G. Stabin 131I Ablation Treatment in Young Females After the Chernobyl Accident J. Nucl. Med., October 1, 2006; 47(10): 1723 - 1727. [Abstract] [Full Text] [PDF]

				P. R. Schroeder, B. R. Haugen, F. Pacini, C. Reiners, M. Schlumberger, S. I. Sherman, D. S. Cooper, K. G. Schuff, L. E. Braverman, M. C. Skarulis, et al. A Comparison of Short-Term Changes in Health-Related Quality of Life in Thyroid Carcinoma Patients Undergoing Diagnostic Evaluation with Recombinant Human Thyrotropin Compared with Thyroid Hormone Withdrawal J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 878 - 884. [Abstract] [Full Text] [PDF]

				S. Tagay, S. Herpertz, M. Langkafel, Y. Erim, L. Freudenberg, N. Schopper, A. Bockisch, W. Senf, and R. Gorges Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment Eur. J. Endocrinol., December 1, 2005; 153(6): 755 - 763. [Abstract] [Full Text] [PDF]

				S. Iorcansky, V. Herzovich, R. R. Qualey, and R. M. Tuttle Serum Thyrotropin (TSH) Levels after Recombinant Human TSH Injections in Children and Teenagers with Papillary Thyroid Cancer J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6553 - 6555. [Abstract] [Full Text] [PDF]

				M. Luster, F. Lippi, B. Jarzab, P. Perros, M. Lassmann, C. Reiners, and F. Pacini rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review Endocr. Relat. Cancer, March 1, 2005; 12(1): 49 - 64. [Abstract] [Full Text] [PDF]

				D. I. Serhal, M. P. Nasrallah, and B. M. Arafah Rapid Rise in Serum Thyrotropin Concentrations after Thyroidectomy or Withdrawal of Suppressive Thyroxine Therapy in Preparation for Radioactive Iodine Administration to Patients with Differentiated Thyroid Cancer J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3285 - 3289. [Abstract] [Full Text] [PDF]

				A. A. Driedger and N. Kotowycz Two Cases of Thyroid Carcinoma That Were Not Stimulated by Recombinant Human Thyrotropin J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 585 - 590. [Abstract] [Full Text] [PDF]

				F. Pacini, E. Molinaro, M. G. Castagna, L. Agate, R. Elisei, C. Ceccarelli, F. Lippi, D. Taddei, L. Grasso, and A. Pinchera Recombinant Human Thyrotropin-Stimulated Serum Thyroglobulin Combined with Neck Ultrasonography Has the Highest Sensitivity in Monitoring Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3668 - 3673. [Abstract] [Full Text] [PDF]

				C. Menzel, W. T. Kranert, N. Dobert, M. Diehl, T. Fietz, N. Hamscho, U. Berner, and F. Grunwald rhTSH Stimulation Before Radioiodine Therapy in Thyroid Cancer Reduces the Effective Half-Life of 131I J. Nucl. Med., July 1, 2003; 44(7): 1065 - 1068. [Abstract] [Full Text] [PDF]

				R. J. Robbins and K. S. Pentlow Coming of Age: Recombinant Human Thyroid-Stimulating Hormone as a Preparation for 131I Therapy in Thyroid Cancer J. Nucl. Med., July 1, 2003; 44(7): 1069 - 1071. [Full Text] [PDF]

				J. C. Sisson, B. L. Shulkin, and S. Lawson Increasing Efficacy and Safety of Treatments of Patients with Well-Differentiated Thyroid Carcinoma by Measuring Body Retentions of 131I J. Nucl. Med., June 1, 2003; 44(6): 898 - 903. [Abstract] [Full Text] [PDF]

				R. J. Robbins and A. K. Robbins Recombinant Human Thyrotropin and Thyroid Cancer Management J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1933 - 1938. [Full Text] [PDF]

				G. Vitale, G. A. Lupoli, A. Ciccarelli, A. Lucariello, M. R. Fittipaldi, F. Fonderico, A. Panico, and G. Lupoli Influence of Body Surface Area on Serum Peak Thyrotropin (TSH) Levels after Recombinant Human TSH Administration J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1319 - 1322. [Abstract] [Full Text] [PDF]

				B. Biondi, E. A. Palmieri, L. Pagano, M. Klain, G. Scherillo, M. Salvatore, G. Fenzi, G. Lombardi, and S. Fazio Cardiovascular Safety of Acute Recombinant Human Thyrotropin Administration to Patients Monitored for Differentiated Thyroid Cancer J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 211 - 214. [Abstract] [Full Text] [PDF]

				V. Muller, K. H. Bohuslavizki, S. Klutmann, and M. Clausen Value of Recombinant Human Thyrotropin in High-Dose Radioiodine Therapy: A Case Report J. Nucl. Med. Technol., December 1, 2002; 30(4): 185 - 188. [Abstract] [Full Text] [PDF]

				F. Saremi, H. Jadvar, and M. E. Siegel Pharmacologic Interventions in Nuclear Radiology: Indications, Imaging Protocols, and Clinical Results RadioGraphics, May 1, 2002; 22(3): 477 - 490. [Abstract] [Full Text] [PDF]

				M. W. Szkudlinski, V. Fremont, C. Ronin, and B. D. Weintraub Thyroid-Stimulating Hormone and Thyroid-Stimulating Hormone Receptor Structure-Function Relationships Physiol Rev, April 1, 2002; 82(2): 473 - 502. [Abstract] [Full Text] [PDF]

				M. Braga, M. D. Ringel, and D. S. Cooper Sudden Enlargement of Local Recurrent Thyroid Tumor after Recombinant Human TSH Administration J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5148 - 5151. [Abstract] [Full Text] [PDF]

				A. David, A. Blotta, M. Bondanelli, R. Rossi, E. Roti, L. E. Braverman, L. Busutti, and E. C. d. Uberti Serum Thyroglobulin Concentrations and 131I Whole-Body Scan Results in Patients with Differentiated Thyroid Carcinoma After Administration of Recombinant Human Thyroid-Stimulating Hormone J. Nucl. Med., October 1, 2001; 42(10): 1470 - 1475. [Abstract] [Full Text] [PDF]

				J. C. Sisson and J. E. Carey Thyroid Carcinoma with High Levels of Function: Treatment with 131I J. Nucl. Med., June 1, 2001; 42(6): 975 - 983. [Abstract] [Full Text] [PDF]

				M. S. T. Torres, L. Ramirez, P. H. Simkin, L. E. Braverman, and C. H. Emerson Effect of Various Doses of Recombinant Human Thyrotropin on the Thyroid Radioactive Iodine Uptake and Serum Levels of Thyroid Hormones and Thyroglobulin in Normal Subjects J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1660 - 1664. [Abstract] [Full Text]

				R. J. Robbins, R. M. Tuttle, R. N. Sharaf, S. M. Larson, H. K. Robbins, R. A. Ghossein, A. Smith, and W. D. Drucker Preparation by Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal Are Comparable for the Detection of Residual Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 619 - 625. [Abstract] [Full Text]

				M. Luster, M. Lassmann, H. Haenscheid, U. Michalowski, C. Incerti, and C. Reiners Use of Recombinant Human Thyrotropin before Radioiodine Therapy in Patients with Advanced Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3640 - 3645. [Abstract] [Full Text]

				P. Rotman-Pikielny, J. C. Reynolds, W. C. Barker, P. M. Yen, M. C. Skarulis, and N. J. Sarlis Recombinant Human Thyrotropin for the Diagnosis and Treatment of a Highly Functional Metastatic Struma Ovarii J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 237 - 244. [Abstract] [Full Text]

				G. E. Vargas, H. Uy, C. Bazan, T. A. Guise, and J. M. Bruder Hemiplegia after Thyrotropin Alfa in a Hypothyroid Patient with Thyroid Carcinoma Metastatic to the Brain J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3867 - 3871. [Full Text]

				B. R. Haugen, F. Pacini, C. Reiners, M. Schlumberger, P. W. Ladenson, S. I. Sherman, D. S. Cooper, K. E. Graham, L. E. Braverman, M. C. Skarulis, et al. A Comparison of Recombinant Human Thyrotropin and Thyroid Hormone Withdrawal for the Detection of Thyroid Remnant or Cancer J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3877 - 3885. [Abstract] [Full Text]

				F. A. Fares, S. Yamabe, D. Ben-Menahem, M. Pixley, A. J. W. Hsueh, and I. Boime Conversion of Thyrotropin Heterodimer to a Biologically Active Single-Chain Endocrinology, May 1, 1998; 139(5): 2459 - 2464. [Abstract] [Full Text] [PDF]

				P. W. Ladenson, L. E. Braverman, E. L. Mazzaferri, F. Brucker-Davis, D. S. Cooper, J. R. Garber, F. E. Wondisford, T. F. Davies, L. J. DeGroot, G. H. Daniels, et al. Comparison of Administration of Recombinant Human Thyrotropin with Withdrawal of Thyroid Hormone for Radioactive Iodine Scanning in Patients with Thyroid Carcinoma N. Engl. J. Med., September 25, 1997; 337(13): 888 - 896. [Abstract] [Full Text] [PDF]

				L. Ramirez, L. E. Braverman, B. White, and C. H. Emerson Recombinant Human Thyrotropin Is a Potent Stimulator of Thyroid Function in Normal Subjects J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2836 - 2839. [Abstract] [Full Text] [PDF]

				M. Grossmann, B. D. Weintraub, and M. W. Szkudlinski Novel Insights into the Molecular Mechanisms of Human Thyrotropin Action: Structural, Physiological, and Therapeutic Implications for the Glycoprotein Hormone Family Endocr. Rev., August 1, 1997; 18(4): 476 - 501. [Abstract] [Full Text] [PDF]

				C. H. Emerson and R. Colzani Epithelial Cell Thyroid Cancer and Thyroid Stimulating Hormone--When Less is More J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 9 - 10. [Full Text] [PDF]

				A. Z. Rudavsky and L. M. Freeman Treatment of Scan-Negative, Thyroglobulin-Positive Metastatic Thyroid Cancer Using Radioiodine 131I and Recombinant Human Thyroid Stimulating Hormone J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 11 - 14. [Full Text] [PDF]

				M. Grossmann, R. Wong, N. G. Teh, J. E. Tropea, J. East-Palmer, B. D. Weintraub, and M. W. Szkudlinski Expression of Biologically Active Human Thyrotropin (hTSH) in a Baculovirus System: Effect of Insect Cell Glycosylation on hTSH Activity in Vitro and in Vivo Endocrinology, January 1, 1997; 138(1): 92 - 100. [Abstract] [Full Text] [PDF]

				M. Grossmann, M. W. Szkudlinski, J. E. Tropea, L. A. Bishop, N. R. Thotakura, P. R. Schofield, and B. D. Weintraub Expression of Human Thyrotropin in Cell Lines with Different Glycosylation Patterns Combined with Mutagenesis of Specific Glycosylation Sites J. Biol. Chem., December 8, 1995; 270(49): 29378 - 29385. [Abstract] [Full Text] [PDF]

				H. Leitolf, K. P. T. Tong, M. Grossmann, B. D. Weintraub, and M. W. Szkudlinski Bioengineering of Human Thyrotropin Superactive Analogs by Site-directed "Lysine-scanning" Mutagenesis. COOPERATIVE EFFECTS BETWEEN PERIPHERAL LOOPS J. Biol. Chem., August 25, 2000; 275(35): 27457 - 27465. [Abstract] [Full Text] [PDF]